knowledge -WSS

knowledge

author：fashion 2025-10-01 18:22:52 - browse：55288

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Change Healthcare outage fallout shows need for new oversight

WSS

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Ebola: Gilead Sciences antiviral shows promise as new treatment

Steward Health Care Massachusetts hospitals face fiscal disaster

UCLA team creates talking throat patch for voice disorders

A solution to the after

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

entertainment

knowledge

focus

In age of alternative facts, a scholarly course on calling out crap

PBM reform efforts get punted in Congress

Walensky prepares to leave CDC — and Congress — behind

UCLA team creates talking throat patch for voice disorders

Peter Hotez and the public health issue of online harassment

Obesity drugs seen as possible treatment for liver disease MASH

At least 13 dead in Texas as scorching temps continue

A new nitrogen execution bill also undermines medical licensing

Medical records are filled with copy

A new nitrogen execution bill also undermines medical licensing

knowledge

A new nitrogen execution bill also undermines medical licensing

WuXi out of biotech trade group, U.S. and China relations to blame

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Dario to buy mental health app maker Twill in cash and stock deal

Wikipedia

focus

hotspot

knowledge